• News
AACR-2022 NI-2601 & NI-2901 CD47xPD-L1 bispecific antibodies

AACR-2022 NI-2601 & NI-2901 CD47xPD-L1 bispecific antibodies

AACR Annual Meeting 202- Xavier Chauchet -


Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes

The American Association for Cancer Research (AACR) will host its Annual Meeting April 8-13, 2022. Light Chain Bioscience is very pleased to have Xavier Chauchet attend in-person.

Xavier will be presenting two posters #3225 and #3283 describing differentiating CD47xPD-L1 bispecific #antibody approaches, NI-2601 & NI-2901.

“NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors (#3283) will be exposed and presented on April 12 between 1:30-5:00 p.m.

Read 1st poster - Poster section 32 [PDF]:

aacr 2022 ni 2901 cd47xpd l1 bispecific antibody for dual immune checkpoint blockade 2601

NI-2901, a CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution (#3225) will be exposed and presented on April 12 between 1:30-5:00 p.m.

Read 2nd poster - Poster section 32 [PDF] :

aacr 2022 ni 2901 cd47xpd l1 bispecific antibody for dual immune checkpoint blockade 2901


Ernest N. Morial Convention Center New Orleans, Louisiana

900 Convention Center Blvd, New Orleans, LA 70130, United States

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn